

NAME	CTS AFFILIATION	DISCLOSURE	UPDATED
Darcy Marciniuk	COPD Committee (Chair) <u>and</u> Canadian Respiratory Guidelines Committee (CRGC) <u>and</u> Canadian COPD Alliance	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Consultant Fee, Speaker's Bureau, Advisory Committee:</b> AstraZeneca, Boehringer-Ingelheim, Canadian Agency for Drugs and Technologies in Health, GlaxoSmithKline, Health Canada, Health Quality Council of Saskatchewan, Novartis, Nycomed, Pfizer, Prince Albert Grand Council Chronic Disease Network, Public Health Agency of Canada, Saskatoon Health Region</li> <li>▪ <b>Fiduciary Position</b> (other than CTS or CRHP): American College of Chest Physicians, Chest Foundation, Lung Association of Saskatchewan</li> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Boehringer-Ingelheim, Canadian Institutes of Health Research, GlaxoSmithKline, Lung Association of Saskatchewan, Novartis, Pfizer, Public Health Agency of Canada, Royal University Hospital Foundation, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering-Plough</li> </ul>	March 14 <sup>th</sup> , 2011
Shawn Aaron	COPD Committee (Executive)	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline</li> <li>▪ <b>Consultant:</b> Health Canada Therapeutic Products Directorate, Ontario Ministry of Health and Long Term Care</li> </ul>	May 13 <sup>th</sup> , 2010
Pat Bailey	COPD Committee	<p>Over the last two years, I have NOT had any affiliations (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	Jan 7 <sup>th</sup> , 2011
Meyer Balter	COPD Committee (Executive) <u>and</u> Canadian Respiratory Guidelines Committee (CRGC)	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer</li> <li>▪ <b>Speaker:</b> AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Nycomed, Pfizer</li> </ul>	May 4 <sup>th</sup> , 2010

Donna Bleakney	External Reviewer	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	May 12 <sup>th</sup> , 2010
Dina Brooks	COPD Committee <u>and</u> Canadian COPD Alliance <u>and</u> CRC Planning Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest	April 29 <sup>th</sup> , 2010
Scott Butcher	COPD Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	April 29 <sup>th</sup> , 2010
Richard Debigare	COPD Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	April 29 <sup>th</sup> , 2010
Gail Dechman	COPD Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Research/Program Grant Funding:</b> Dalhousie University, Lung Association of Nova Scotia, Nova Scotia Health Research Foundation, Social Sciences and Humanities Research Council</li> <li>▪ <b>Membership</b> (other than CTS or CRHP): ATS, AACVPR, Canadian Physiotherapy Association, Nova Scotia College of Physiotherapy, Nova Scotia Physiotherapy Association</li> </ul>	May 12 <sup>th</sup> , 2010
Gordon Ford	COPD Committee (Executive)	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Honoraria:</b> Abbott, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer, Janssen-Ortho Inc.</li> <li>▪ <b>Appointment:</b> Medical staff, Alberta Health Services</li> <li>▪ <b>Research/Program Grant Funding:</b> Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer</li> </ul>	July 21 <sup>st</sup> , 2010
Donna Goodridge	COPD Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Appointment:</b> University of Saskatchewan, Associate Professor, College of Nursing</li> <li>▪ <b>Speaker:</b> Lilly (sponsored her to attend educational session on depression in COPD for primary care physicians, Sept. 2009)</li> </ul>	January 11 <sup>th</sup> , 2011

Paul Hernandez	COPD Committee (Executive) <u>and</u> Canadian Respiratory Guidelines Committee (CRGC) <u>and</u> Pulmonary Vascular Disease Committee <u>and</u> Canadian COPD Alliance	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Consultant:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Lilly, Merck Frosst, Novartis, Nycomed, Pfizer</li> <li>▪ <b>CME Development and Speaker:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Canadian Respiratory Conference, Atlantic Respirology and Critical Care Conference</li> <li>▪ <b>Medical Advisory Board:</b> Lung Association of Nova Scotia, Canadian COPD Alliance</li> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Lilly, Novartis, Nycomed, Pfizer, Lung Association of Nova Scotia, Canadian Institute of Health Research, Capital Health Research Foundation</li> <li>▪ <b>Reviewer and Consultant:</b> Canadian Agency for Drugs and Technologies in Health</li> </ul>	January 11 <sup>th</sup> , 2011
Vicki Kennedy	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	January 11 <sup>th</sup> , 2011
Julie Lauzon	COPD Committee (A1AT)	<b>Appointment:</b> Clinical staff, University of Calgary	Dec 7 <sup>th</sup> , 2011
Francois Maltais	COPD Committee (Executive)	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> Boehringer-Ingelheim, GlaxoSmithKline</li> <li>▪ <b>Research/Program Grant Funding:</b> Altana Pharma, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst , Novartis, Nycomed</li> <li>▪ <b>Research Chair in COPD:</b> Canadian Institutes of Health Research and GlaxoSmithKline</li> <li>▪ <b>Speaker:</b> Boehringer-Ingelheim, GlaxoSmithKline, Pfizer</li> </ul>	January 11 <sup>th</sup> , 2011

Denis O'Donnell	COPD Committee (Executive) <u>and</u> past President of the Canadian Thoracic Society	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> Boehringer-Ingelheim, Pfizer Canada</li> <li>▪ <b>Consulting Fees and Speaker Bureau/Honoraria:</b> Boehringer-Ingelheim, GlaxoSmithKline, Pfizer Canada</li> <li>▪ <b>Research/Program Grant Funding:</b> Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Pfizer.</li> </ul>	January 11 <sup>th</sup> , 2011
Veronique Pepin	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board and Speaker:</b> GlaxoSmithKline</li> <li>▪ <b>Research/Program Grant Funding:</b> GlaxoSmithKline, Canadian Institutes of Health Research, Canadian Lung Association, Fonds de la recherche en santé du Québec,</li> <li>▪ <b>Reviewer:</b> Fonds de la recherche en santé du Québec</li> </ul>	May 2 <sup>nd</sup> , 2010
Darlene Reid	COPD Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	May 3 <sup>rd</sup> , 2010
Graeme Rocker	COPD Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> Canadian Institutes of Health Research (Panel Scientific Officer)</li> <li>▪ <b>Speaker:</b> GlaxoSmithKline, various Universities, Pfizer (Canada, USA, UK)</li> <li>▪ <b>Research/Program Grant Funding:</b> Canadian Institutes of Health Research, Capital Health, CHEST foundation, Lung Association of Nova Scotia, GlaxoSmithKline, Medical Research Fund New Brunswick, Atlantic Health Sciences Corporation</li> <li>▪ <b>Reviewer or Consultant:</b> CIHR, CMAJ, CHEST, Progress in Palliative Care, J Palliat Care, J Pain Sympt Manage, Annals Intern Med, Guest Editor, J Palliat Care 2011 and Progress in Palliat Care 2011</li> </ul>	January 11 <sup>th</sup> , 2011

William Sheel	COPD Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	May 4 <sup>th</sup> , 2010
Michael Stickland	COPD Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Appointment:</b> Co-director of the Centre for Lung Health, Covenant Health, Edmonton, Alberta</li> <li>▪ <b>Research/Program Grant Funding:</b> GlaxoSmithKline, Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, Alberta Lung Association</li> <li>▪ <b>Speaker:</b> GlaxoSmithKline</li> </ul>	May 9 <sup>th</sup> , 2010
David Todd	COPD Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Research/Program Grant Funding:</b> AstraZeneca, Ontario Thoracic Society</li> </ul>	April 29 <sup>th</sup> , 2010
Shannon Walker	COPD Committee <u>and</u> Membership	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board:</b> AstraZeneca, GlaxoSmithKline, Nycomed</li> <li>▪ <b>Appointments:</b> On-call services, Flame Oxygen, ICU Director, Cardiopulmonary Wellness Center at InterHealth (BC), UBC teacher for residents and medical students</li> <li>▪ <b>Consultant:</b> Boehringer-Ingelheim</li> <li>▪ <b>Speaker:</b> AstraZeneca, BC College of Family Physicians, BC College of Respiratory Therapists, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer</li> </ul>	April 28 <sup>th</sup> , 2010